Reaction

Which drugs are most reported with Hepatocellular carcinoma?

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 7,531 reports · 85 co-occurring drugs

As of the last recalculation, Hepatocellular Carcinoma appears in 7,531 FAERS reports alongside 85 co-occurring drug terms. The strongest observed disproportionality signal is SORAFENIB (PRR 337.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Sorafenib	1,899	337.6	371.7
Sofosbuvir	911	145.0	152.1
Regorafenib	487	123.9	129.3
Atezolizumab	791	62.8	64.1
Ledipasvir And Sofosbuvir	402	61.0	62.3
Entecavir	212	51.6	52.5
Ribavirin	966	47.5	48.2
Velpatasvir And Sofosbuvir	118	25.8	26.0
Tenofovir Disoproxil Fumarate Tablets	68	22.0	22.1
Bevacizumab	776	19.2	19.3
Cabozantinib	266	15.8	15.9
Tenofovir Disoproxil Fumarate	102	8.6	8.7
Lamivudine Oral	73	8.0	8.1
Everolimus Tablets	48	8.0	8.0
Tolvaptan	38	7.3	7.3
Rifaximin	52	6.9	6.9
Lamivudine	75	6.8	6.8
Sirolimus	32	6.6	6.6
Lactulose	89	6.5	6.5
Lenvatinib	73	6.2	6.2
Febuxostat Tablets 40 Mg	22	6.0	6.0
Febuxostat Tablets 80 Mg	22	6.0	6.0
Basiliximab	25	5.9	5.9
Tacrolimus Ointment 0.1%	250	5.7	5.7
Tacrolimus Extended-Release Capsules	250	5.7	5.7
Ursosiol	39	5.6	5.6
Tacrolimus	302	5.5	5.5
Ritonavir 100 Mg	27	5.0	5.0
Ursodiol	39	5.0	5.0
Efavirenz	20	5.0	5.0
Peginterferon Alfa-2A	96	5.0	5.0
Rabeprazole	34	4.3	4.3
Spironolactone	209	4.2	4.2
Mycophenolate Mofetil	202	4.2	4.2
Mycophenolate Mofetil Hydrochloride	202	4.2	4.2
Testosterone	34	4.0	4.0
Durvalumab	28	3.8	3.8
Glecaprevir And Pibrentasvir	15	3.8	3.8
Nevirapine	12	3.7	3.7
Febuxostat	22	3.6	3.6
Imatinib	23	3.6	3.6
Ritonavir	38	3.6	3.6
Everolimus	56	3.1	3.1
Mycophenolic Acid	35	3.0	3.0
Raltegravir	18	3.0	3.0
Propranolol Hydrochloride	77	3.0	3.0
Baricitinib	10	2.9	2.9
Glimepiride	40	2.8	2.8
Valganciclovir	19	2.8	2.8
Valganciclovir Hydrochloride	19	2.8	2.8
Candesartan	33	2.6	2.6
Mycophenilic Acid	19	2.5	2.5
Dorzolamide Hydrochloride And Timolol Maleate	7	2.4	2.5
Valganciclovir Hydrochloride Powder,	10	2.3	2.3
Ganciclovir	8	2.2	2.2
Insulin	43	2.1	2.1
Magnesium Oxide	32	2.1	2.1
Atazanavir	11	2.1	2.1
Ganciclovir Sodium	8	2.1	2.1
Erlotinib	7	2.0	2.0
Ustekinumab	68	1.8	1.8
Rabeprazole Sodium	18	1.8	1.8
Linagliptin	12	1.8	1.8
Emicizumab	8	1.8	1.8
Doxorubicin	57	1.8	1.8
Sitagliptin	46	1.8	1.8
Methoxy Polyethylene Glycol-Epoetin Beta	7	1.8	1.8
Misoprostol	6	1.7	1.7
Darunavir	9	1.6	1.6
Erlotinib Hydrochloride	7	1.5	1.5
Granisetron	5	1.3	1.3
Nivolumab	46	1.3	1.3
Methadone Hydrochloride	5	1.3	1.3
Emtricitabine And Tenofovir Alafenamide	5	1.2	1.2
Gemcitabine	17	1.2	1.2
Cisplatin	32	1.1	1.1
Oxaliplatin	30	1.1	1.1
Guselkumab	13	1.0	1.0
Tafamidis	4	0.9	0.9
Gefitinib	3	0.9	0.9
Ixekizumab	12	0.9	0.9
Suvorexant	4	0.9	0.9
Emtricitabine And Tenofovir Disoproxil Fumarate	13	0.8	0.8
Bictegravir Sodium, Emtricitabine, And Tenofovir Alafenamide Fumarate	4	0.6	0.6
Abiraterone Acetate	9	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.